Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.39 |
| ▸ | PREP | P48147 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4797812 | 0.92 | ACE (0.38) | ACEPREPMEN1KMT2AUSP2 | |
| SCHEMBL4801293 | 0.90 | PREP (0.38) | ACEPREPMEN1KMT2AUSP2 | |
| SCHEMBL4802100 | 0.89 | CYP3A4 (0.41) | ACEPREPCHRM1CYP19A1CYP3A4 | |
| SCHEMBL4795475 | 0.88 | ACE (0.41) | ACEPREPMEN1KMT2AUSP2 | |
| SCHEMBL4800633 | 0.86 | ACE (0.38) | ACEPREPMEN1KMT2AUSP2 | |
| SCHEMBL4797678 | 0.86 | PREP (0.34) | ACEPREPMEN1KMT2AUSP2 | |
| SCHEMBL4800774 | 0.84 | ACE (0.37) | ACEPREPMEN1KMT2AUSP2 | |
| SCHEMBL4800732 | 0.80 | CHRM2 (0.42) | ACEPREPMEN1KMT2AUSP2 | |
| SCHEMBL4798899 | 0.79 | ACE (0.48) | ACEPREPMEN1KMT2AUSP2 | |
| SCHEMBL4802701 | 0.79 | PREP (0.41) | ACEPREPMEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439036-B2 | Process for producing optically active octahydro-1H-indole-2-carboxylic acid | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-10-21 | — | — | US | disclosed |
| EP-1536017-B1 | Process for producing optically active octahydro-1H-indole-2-carboxylic acid | SUMITOMO CHEMICAL CO (JP) | 2007-04-18 | — | — | EP | disclosed |
| EP-1536017-A2 | Process for producing optically active octahydro-1H-indole-2-carboxylic acid | Sumitomo Chemical Company, Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-20050106690-A1 | Process for producing optically active octahydro-1H-indole-2-carboxylic acid | SUMITOMO CHEMICAL COMPANY, LIMITED | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050106690-A1 | Process for producing optically active octahydro-1H-indole-2-carboxylic acid | IDO1, IDO2, APEH | ACE 1148/4885PREP 283/4885MEN1 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.